Acrivon Therapeutics Inc

CFO of Acrivon Therapeutics Buys 8,832 Shares, Signals Confidence Amid Weak Earnings and Market Volatility

Insightful CFO buying of Acrivon Therapeutics signals potential upside amid volatile biotech market – see why insider moves matter for investors.

Acrivon Therapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

16/01/2026, 22:20

3 minutes to read

COO’s Bold Buy Signals Acrivon’s Potential Upside Amid 68% YTD Decline

COO’s 10,000‑share buy of Acrivon Therapeutics signals a confidence shift amid a 67% YTD decline, hinting at a potential rebound with upcoming Phase 1 data.

Acrivon Therapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

15/01/2026, 22:56

3 minutes to read